Successful Dose Reduction of Janus-kinase Inhibitors in Well-controlled Atopic Dermatitis: A Prospective, Multicentre, Real-world Study
Acta Dermato-Venereologica · 17.11.2025 · 105 · adv44165
DOI: 10.2340/actadv.v105.44165 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Dermato-Venereologica, online erschienen am 17.11.2025. Verfasst von Anne R Schlösser und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Drug Tapering, Heterocyclic Compounds, 3-Ring, Janus Kinase 1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Janus kinase 1 (JAK1) inhibitors are effective for atopic dermatitis, but carry risks of adverse events. Dose reduction may mitigate these risks, although real-world evidence of dose reduction strategies is limited. This prospective, real-world study investigated JAK1 inhibitor dose reduction among 60 adults with controlled atopic dermatitis treated with abrocitinib or upadacitinib for ≥ 3 months. Doses were halved or administered every other day, as capsules cannot be split. Patients could resume their original dose if needed. The primary outcome was the proportion of patients maintaining the reduced dose at week 12. Secondary outcomes included physician- and patient-reported measures at baseline, and weeks 4, 8, and 12, analysed using linear mixed-effects models. At week 12, 80% (48/60) maintained the reduced dose. All outcomes remained within treat-to-target goals for atopic dermatitis at week 12, except for POEM (mean 8.87, 95% CI 7.43–10.31). While disease activity was significantly increased at week 8, no changes were seen at week 12. Absolute changes did not exceed the minimal clinically important difference. All 8 patients who resumed their initial dose regained disease control at week 12. In conclusion, JAK1 inhibitor dose reduction was feasible in 80% of patients without a clinically meaningful increase in disease activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Dermatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
- Department of Biostatistics, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands. dirkjan.hijnen@radboudumc.nl.
ORCID-Profile: Anouk G M Caron, Sara J Baart, Louise A A Gerbens, Phyllis I Spuls, Tamar E C Nijsten, Renske Schappin, DirkJan Hijnen
Zitieren
APA
Schlösser, A. R., Caron, A. G. M., Den Ouden, M. S., Baart, S. J., Gerbens, L. A. A., Spuls, P. I., Nijsten, T. E. C., Schappin, R., & Hijnen, D. (2025). Successful Dose Reduction of Janus-kinase Inhibitors in Well-controlled Atopic Dermatitis: A Prospective, Multicentre, Real-world Study. Acta Dermato-Venereologica, 105, adv44165. https://doi.org/10.2340/actadv.v105.44165
Vancouver
Schlösser AR, Caron AGM, Den Ouden MS, Baart SJ, Gerbens LAA, Spuls PI, et al. Successful Dose Reduction of Janus-kinase Inhibitors in Well-controlled Atopic Dermatitis: A Prospective, Multicentre, Real-world Study. Acta Dermato-Venereologica. 2025;105:adv44165. doi:10.2340/actadv.v105.44165
BibTeX
@article{Schlsser2025,
author = {Schlösser, Anne R and Caron, Anouk G M and Den Ouden, Merle S and Baart, Sara J and Gerbens, Louise A A and Spuls, Phyllis I and Nijsten, Tamar E C and Schappin, Renske and Hijnen, DirkJan},
title = {Successful Dose Reduction of Janus-kinase Inhibitors in Well-controlled Atopic Dermatitis: A Prospective, Multicentre, Real-world Study},
journal = {Acta Dermato-Venereologica},
year = {2025},
volume = {105},
pages = {adv44165},
doi = {10.2340/actadv.v105.44165}
}
EUVIMED